| Autor: |
Kenneth C. Anderson, Atsushi Iwama, Teruhiro Utsugi, Paul G. Richardson, Yu-Tzu Tai, Jiro Minami, Gullu Gorgun, Diana Cirstea, Jana Jakubikova, Francesca Cottini, Yasuhiro Yoshida, Shohei Kikuchi, Ola Rizq, Hiroto Ohguchi, Rikio Suzuki, Toshiyasu Shimomura, Teru Hideshima, Naoya Mimura |
| Rok vydání: |
2023 |
| Popis: |
PDF file - 648K, Figure S1. TAS-117 is a novel potent and selective inhibitor of Akt kinases. Figure S2. Basal expression of phosphorylated Akt and Akt in MM cell lines. Figure S3. TAS-117 inhibits neither MEK/ERK nor JAK2/STAT pathway. Figure S4. TAS-117 modulates phenotype of side population (SP) cells and induces cytotoxicity in SP cells associated with Akt inhibition. Figure S5. TAS-117 overcomes cytoprotective effects conferred by cytokines by blocking Akt activation. Figure S6. TAS-117 treatment does not affect viability in BMSCs. Figure S7. TAS-117 triggers cleavage of caspase and PARP in MM cells. Figure S8. TAS-117 induces autophagosome formation in MM cells. Figure S9. TAS-117 in combination with bortezomib does not affect body weight of mice. Figure S10. TAS-117 in combination with carfilzomib induces synergistic cytotoxicity in RPMI8226 cells with low baseline of p-Akt, associated with inhibition of carfilzomib-induced p-Akt. Table S1. TAS-117 combination indices (CI) with bortezomib in MM.1S cells. Table S2. TAS-117 combination indices (CI) with bortezomib in RPMI8226 cells. Table S3. TAS-117 combination indices (CI) with carfilzomib in MM.1S cells. Table S4. TAS-117 combination indices (CI) with carfilzomib in RPMI8226 cells. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
